19,397,402 Common Stock of Aquestive Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-JAN-2019.
January 20, 2019
Share
19,397,402 Common Stock of Aquestive Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-JAN-2019. These Common Stock will be under lockup for 181 days starting from 24-JUL-2018 to 21-JAN-2019.
Details:
The company along with its directors, executive officers and substantially all of other stockholders and option holders, have agreed that for a period of 180 days after the date of this prospectus, subject to specified exceptions, will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of common stock without the consent of BMO Capital Markets Corp. and RBC Capital Markets, LLC.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Companyâs Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.